Investor Presentaiton
☐
Among the top 20 and one of the fastest growing
generic companies in US
Started operations in 2005 and adopted a
"Customer Centric Model"
Ranked 12th amongst the top US generic
companies based on scripts (Source: IMS)
Among the top three players in the market for
nine out of the top ten products marketed
"Preferred Supplier" for many customers.
Focusing on delivery based, difficult to make
products, the next growth driver
3.984
Sales in US (Rs. Mio.)
9,655
▲ 44%
6,715
▲ 69%
FY 08-09
FY 09-10
FY 10-11
DMF Filings
ANDA Filings
ANDA Approvals
Products Launched
40
10
99
65
97
130
KEY REGULATORY STRENGTHS
A robust regulatory pipeline
Over half of the products use own API
Started filing ANDAs for Nasal (5 so far)
and Parenterals (18 so far)
Plan to file 12 -15 ANDAS p.a.
10
10View entire presentation